Enzo Biochem Revenue 2010-2023 | ENZ
Enzo Biochem revenue from 2010 to 2023. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sales of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
Enzo Biochem Annual Revenue
(Millions of US $) |
| 2022 |
$107 |
| 2021 |
$118 |
| 2020 |
$76 |
| 2019 |
$81 |
| 2018 |
$101 |
| 2017 |
$105 |
| 2016 |
$103 |
| 2015 |
$98 |
| 2014 |
$96 |
| 2013 |
$94 |
| 2012 |
$103 |
| 2011 |
$102 |
| 2010 |
$97 |
| 2009 |
$90 |
Enzo Biochem Quarterly Revenue
(Millions of US $) |
| 2023-01-31 |
$16 |
| 2022-10-31 |
$18 |
| 2022-07-31 |
$20 |
| 2022-04-30 |
$26 |
| 2022-01-31 |
$34 |
| 2021-10-31 |
$27 |
| 2021-07-31 |
$25 |
| 2021-04-30 |
$33 |
| 2021-01-31 |
$31 |
| 2020-10-31 |
$29 |
| 2020-07-31 |
$20 |
| 2020-04-30 |
$17 |
| 2020-01-31 |
$19 |
| 2019-10-31 |
$20 |
| 2019-07-31 |
$21 |
| 2019-04-30 |
$20 |
| 2019-01-31 |
$19 |
| 2018-10-31 |
$21 |
| 2018-07-31 |
$23 |
| 2018-04-30 |
$25 |
| 2018-01-31 |
$26 |
| 2017-10-31 |
$27 |
| 2017-07-31 |
$25 |
| 2017-04-30 |
$27 |
| 2017-01-31 |
$26 |
| 2016-10-31 |
$26 |
| 2016-07-31 |
$27 |
| 2016-04-30 |
$26 |
| 2016-01-31 |
$25 |
| 2015-10-31 |
$25 |
| 2015-07-31 |
$26 |
| 2015-04-30 |
$24 |
| 2015-01-31 |
$23 |
| 2014-10-31 |
$25 |
| 2014-07-31 |
$25 |
| 2014-04-30 |
$24 |
| 2014-01-31 |
$23 |
| 2013-10-31 |
$24 |
| 2013-07-31 |
$23 |
| 2013-04-30 |
$23 |
| 2013-01-31 |
$22 |
| 2012-10-31 |
$26 |
| 2012-07-31 |
$26 |
| 2012-04-30 |
$26 |
| 2012-01-31 |
$25 |
| 2011-10-31 |
$26 |
| 2011-07-31 |
$27 |
| 2011-04-30 |
$26 |
| 2011-01-31 |
$24 |
| 2010-10-31 |
$26 |
| 2010-07-31 |
$25 |
| 2010-04-30 |
$24 |
| 2010-01-31 |
$23 |
| 2009-10-31 |
$25 |
| 2009-07-31 |
$25 |
| 2009-04-30 |
$23 |
| 2009-01-31 |
$21 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.114B |
$0.107B |
|
Enzo Biochem, Inc. develops, manufactures and markets health care products based on molecular biology and genetic engineering techniques, and also provides diagnostic services to the medical community. The business activities of the company are performed by one of the company's three wholly-owned subsidiaries--Enzo Diagnostics, Inc., Enzo Therapeutics, Inc., and Enzo Clinical Labs, Inc. The primary focus of the company's research is the development of products based on two technology platforms -- genetic modulation and immune modulation.
|
